title: Presentation and role of transplantation in adult patients with type 1 primary hyperoxaluria and the I244T AGXT mutation: Single-center experience.
abstract: Primary hyperoxaluria type 1 (PH1) is a rare genetic disorder characterized by allelic and clinical heterogeneity. We aim to describe the presentation and full single-center experience of the management of PH1 patients bearing the mutation described in our community (I244T mutation+polymorphism P11L). Since 1983, 12 patients with recurrent renal lithiasis have been diagnosed with PH1 and renal failure in the Canary Islands, Spain. Diagnostic confirmation was based on the presence of oxalosis in undecalcified bone or kidney allograft biopsy, reduced alanine:glyoxylate aminotransferase activity in liver biopsy, and blood DNA analysis. Patients underwent different treatment modalities depending on individual clinical circumstances and therapeutic possibilities at the time of diagnosis: hemodialysis, isolated kidney, simultaneous liver-kidney, or pre-emptive liver transplantation. In all cases, the presentation of advanced renal disease was relatively late (>13 years) and no cases were reported during lactancy or childhood. The eight patients treated with hemodialysis or isolated kidney transplantation showed unfavorable evolution leading to death over a variable period of time. In contrast, the four patients undergoing liver transplantation (three liver+kidney and one pre-emptive liver alone) showed favorable long-term allograft and patient survival (up to 12 years follow-up). In conclusion, in this PH1 population, all bearing the I244T mutation, the development of end-stage renal disease was distinctive during late adolescence or adulthood. Our long-term results support pre-emptive liver transplantation at early stages of renal failure, and kidney-liver transplantation for those with advanced renal disease.
authors.affiliation: Nephrology Section, Hospital Universitario de Canarias, Santa Cruz de Tenerife, La Laguna, Spain. viclorenzo@terra.es
authors.forename: V
authors.initials: V
authors.lastname: Lorenzo
authors.forename: A
authors.initials: A
authors.lastname: Alvarez
authors.forename: A
authors.initials: A
authors.lastname: Torres
authors.forename: V
authors.initials: V
authors.lastname: Torregrosa
authors.forename: D
authors.initials: D
authors.lastname: Hernández
authors.forename: E
authors.initials: E
authors.lastname: Salido
mesh_terms: D000293:Adolescent; D000328:Adult; D005260:Female; D005500:Follow-Up Studies; D006785:Hospitals, University; D006801:Humans; D006960:Hyperoxaluria, Primary / Q000150:complications / Q000175:diagnosis / Q000401:mortality / Q000601:surgery* / Q000628:therapy; D007676:Kidney Failure, Chronic / Q000601:surgery; D016030:Kidney Transplantation / Q000502:physiology*; D016031:Liver Transplantation / Q000502:physiology*; D008297:Male; D008875:Middle Aged; D009154:Mutation; D010070:Oxalates / Q000652:urine; D011110:Polymorphism, Genetic; D012189:Retrospective Studies; D013030:Spain; D016019:Survival Analysis; D013997:Time Factors; D000637:Transaminases / Q000235:genetics*; D016896:Treatment Outcome
chemical_list: D010070:Oxalates; D000637:Transaminases; C019635:Alanine-glyoxylate transaminase